Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 23, 2026

Back to today

From X

@kevin__mak

Kevin Mak on X

$CMPS Lots to be excited about for the company and the space. Specifically there's been a lot of "thematic" interest in the psychedelics/psilocybin space in the last few weeks, and I expect that to continue. The most notable event recently is an article published in the New England Journal of Medicine: "FDA's New Framework for Psychedelic Drugs" (paywall) https://t.co/rdkgp5GsOG This was co-authored by Michael Davis (just named permanent director of CDER) and the FDA's top psychiatry and neuroscience reviewers. They're the group that ultimately approves/rejects COMP360 (and other psychedelic drugs). Aside from approve/reject, they will be helping negotiate/decide the "label" and essentially how permissive or strict the availability of these drugs/therapies are. The devil is in the details and hearing the FDA publicly state that they are aligned, i.e. "let's make sure these drugs get to market safely AND effectively" versus "this is weird/different, lets be extra cautious/slow with the roll out" is very important to both shareholders, and patients who could potentially be helped by these therapies. Another interesting article is here: WSJ: "Elon Musk's Inner Circle is Pouring Cash Into Making Psychedelics Mainstream" https://t.co/pfuE6JqBGD It is widely expected that COMP360 from $CMPS is going to be the first classic psychedelic (Psilocybin) drug to be approved and commercially available. Despite this being "priced in" by people who follow markets (or the industry) closely, I believe there's a good chance there's a positive public reaction to the headline when/if it comes out in the coming months. More importantly, I think we're at the very early innings of a treatment category that will be highly beneficial to a group of patients who historically have not had great treatment options. My full write on $CMPS is below, I have a $45 price target: https://t.co/rVZOU3yIz6 Disclosure: Creek Drive and its affiliated funds does hold a long position in CMPS. Views expressed are current opinions for informational educational only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in bio for more important information.

Investor Letters

All letters

Capital Wars

CoreWeave’s $35 billion to $39 billion 2026 spending plan relies on debt as unsecured yields reach 15%, making its GPU cloud expansion a…

CRWV $30B
Net Interest 12 clicks

Putting bear cases to rest

Medpace authorized $1 billion of buybacks through 2028 after Q3 revenue rose 8.5% to $716 million; service revenue grew roughly 12% as…

MEDP $19B
Best Anchor Stocks 15 clicks
CLF · long

Cleveland-cliffs INC

Cleveland-Cliffs is pitched as a long on underappreciated earnings power, with more than 90% return potential over six to nine months.

CLF $7.9B
Value Investors Club

MYR Group q3’26 Earnings Preview

MYR Group’s Q3 2026 preview cites data-center and power transmission demand, with long-term service agreements supporting margin growth and…

MYRG $4.2B
Monte Independent Investment Research 6 clicks

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.8B
Latticework by MOI Global 34 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.8B
Latticework by MOI Global 5 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 64 of 258

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.